Market News (Page 5) - TendieTensor

Market News Page 5 of 278 • 6,936 articles

$12.25+ Bn Airline Route Planning Software Markets, 2020-2025, 2025-2030F, 2035F

GlobeNewswire Inc. • Researchandmarkets.Com

$12.25+ Bn Airline Route Planning Software Markets, 2020-2025, 2025-2030F, 2035F

01/09/2026 09:58 AM • The airline route planning software market is experiencing robust growth, expanding from $8.36 billion in 2025 to a projected $12.27 billion by 2030 with a 7.9% CAGR. Growth is driven by AI-driven predictive tools, real-time data integration, weather intelligence, and increased air travel demand. Key players are leveraging satellite-based tracking and forming strategic partnerships to enhance operational efficiency.

SATS - Mentioned as a top holding but no specific analysis provided
BA - Listed as a prominent industry player in the expanding airline route planning software market, benefiting from growing demand for optimization solutions.

#airline route planning software #market growth #AI-driven predictive tools #real-time data analytics #fuel efficiency #cloud platforms #strategic partnerships #operational efficiency

PRMB INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Primo Brands

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

PRMB INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Primo Brands

01/09/2026 09:55 AM • A federal securities class action has been filed against Primo Brands Corporation for allegedly making false and misleading statements about its merger with BlueTriton Brands. The company claimed the merger would accelerate growth and achieve synergies, but integration failures including supply disruptions, warehouse closures, and technology issues emerged in August 2025. The stock plummeted 36% in two trading sessions after the company slashed guidance and replaced its CEO in November 2025. Investors have until January 12, 2026 to seek lead plaintiff status.

NYT - Mentioned as a top holding but no specific analysis provided
PRMB - The company is accused of securities fraud related to misleading statements about merger benefits. Actual merger integration caused significant operational disruptions, resulting in a 36% stock price drop and CEO replacement. Investors suffered substantial losses due to undisclosed problems.

#securities fraud #class action lawsuit #merger integration #false statements #stock price decline #CEO replacement #guidance reduction

$27.99 Generative Artificial Intelligence (GAI) Media Software Global Markets, 2019-2024, 2024-2029F, 2034F

GlobeNewswire Inc. • Researchandmarkets.Com

$27.99 Generative Artificial Intelligence (GAI) Media Software Global Markets, 2019-2024, 2024-2029F, 2034F

01/09/2026 09:55 AM • The generative AI media software market is experiencing explosive growth, expanding from $6.39 billion in 2024 to $8.61 billion in 2025 with a 34.6% CAGR, projected to reach $27.99 billion by 2029. Growth is driven by increased demand for automated content creation, AI-driven video editing, personalized media experiences, and social media proliferation, with Asia-Pacific emerging as a high-growth region alongside North America's current market leadership.

GWRE - Mentioned as a top holding but no specific analysis provided
MSFT - Listed as a prominent player in the rapidly growing generative AI media software market with strong market expansion projected through 2029.

#generative AI #media software #content creation #video editing #market growth #Asia-Pacific #AI automation #personalization

Investing.com • Timothy Fries

Intel Gets a Sentiment Boost as Trump Support Reframes the Stock’s Risk Profile

01/09/2026 09:54 AM • Intel stock surged on January 9, 2026, following President Trump's enthusiastic endorsement of the chipmaker and CEO Lip-Bu Tan on Truth Social. The stock climbed 2.63% to $42.19 after Trump praised Intel's leadership and highlighted the government's $8.9 billion investment stake, which has grown to over $18 billion in value. Trump also celebrated Intel's launch of sub-2-nanometer CPU processors at CES 2026, marking a significant domestic semiconductor manufacturing achievement.

HCA - Mentioned as a top holding but no specific analysis provided
INTC - Stock surged 2.63% following Trump's enthusiastic endorsement and praise of CEO Lip-Bu Tan. Trump highlighted the government's $8.9 billion investment growing to $18 billion in value and celebrated Intel's technological achievement with sub-2-nanometer processor launch. Melius Research also upgraded the stock to 'Buy' with a $50 price target, indicating positive analyst sentiment despite mixed recovery prospects.

#Intel #Trump endorsement #semiconductor manufacturing #CHIPS Act #sub-2-nanometer processors #stock surge #government investment #domestic chip production

5 Under-the-Radar Consumer Staples Stocks With Pricing Power

Investing.com • Chris Markoch

5 Under-the-Radar Consumer Staples Stocks With Pricing Power

01/09/2026 09:43 AM • Consumer staples stocks underperformed in 2025, but mid-cap names with pricing power and margin protection strategies present opportunities for 2026. Five beaten-down stocks—Hormel Foods, Conagra Brands, Lamb Weston, Post Holdings, and J.M. Smucker—offer solid earnings growth projections, attractive valuations, and dividend yields, with upside potential ranging from 21% to 30%.

SHC - Mentioned as a top holding but no specific analysis provided
HRL - Despite 25% stock decline in 2025 due to tariffs and operational issues, company maintains strong top-line growth and dual pricing power through branded products (SPAM, Applegate, Skippy) and private label manufacturing. Consensus price target of $28.20 implies 28% upside, plus 60-year dividend king status with 5.12% yield.

#consumer staples #pricing power #margin protection #dividend stocks #mid-cap stocks #2026 outlook #value-conscious consumers

Q4 Earnings Preview: Wall Street’s Make-or-Break Moment as Reporting Season Looms

Investing.com • Jesse Cohen

Q4 Earnings Preview: Wall Street’s Make-or-Break Moment as Reporting Season Looms

01/09/2026 09:32 AM • Q4 2025 earnings season begins with major banks leading, as the S&P 500 sits near all-time highs. Analysts expect 8.3% EPS growth and 7.6% revenue growth, with the tech sector leading at 25.7% EPS growth driven by AI demand. Forward P/E ratios are stretched at 21.8, suggesting market valuations could amplify reactions to earnings beats or misses.

AMJB - Major bank kicking off earnings season; investment banking rebounding with focus on fee income and loan growth expected to set positive tone for the season.

#Q4 earnings #earnings season #S&P 500 #AI demand #tech sector #valuation #EPS growth #guidance

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

GlobeNewswire Inc. • Not Specified

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

01/09/2026 09:00 AM • Akari Therapeutics announced progress in 2025 and outlined its path toward clinical transition in 2026. The company established a manufacturing partnership with WuXi Biologics and initiated pre-filing activities, with plans to launch its First-in-Human clinical trial by late 2026/early 2027. The company's lead candidate AKTX-101 is an ADC targeting Trop2 with a novel PH1 spliceosome-modulating payload designed to deliver dual mechanisms of action: direct tumor cytotoxicity and immune activation.

CGEMY - Mentioned as part of Delaporte's professional background, with no direct impact on current business performance
AKTX - Company achieved key milestones in 2025 including manufacturing partnership with WuXi Biologics, initiated CMC activities, and is on track for clinical trial initiation by late 2026/early 2027. Preclinical data shows promising efficacy and safety profile for lead candidate AKTX-101 with potential synergy with checkpoint inhibitors.

#antibody drug conjugates (ADCs) #oncology #PH1 payload #AKTX-101 #clinical trial #spliceosome modulation #immuno-oncology #Trop2 receptor #manufacturing partnership

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)

GlobeNewswire Inc. • Orion Corporation

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)

01/09/2026 09:00 AM • BlackRock, Inc. has reduced its ownership stake in Orion Corporation below the 5% disclosure threshold as of January 8, 2026. Separately, Orion Pharma announced the initiation of the TEADES Phase 2 clinical trial for ODM-212 in treating Malignant Pleural Mesothelioma and Epithelioid Hemangioendothelioma.

BLK - The reduction of stake below 5% is a routine portfolio adjustment and does not indicate positive or negative sentiment toward Orion. It is a factual disclosure of ownership change without inherent positive or negative implications.

#BlackRock stake reduction #shareholder disclosure #ODM-212 #Phase 2 trial #Malignant Pleural Mesothelioma #Epithelioid Hemangioendothelioma #clinical trial

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

GlobeNewswire Inc. • Orion Corporation

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

01/09/2026 09:00 AM • BlackRock, Inc. and its funds have reduced their ownership stake in Orion Corporation below the 5% disclosure threshold as of January 8, 2026. The position decreased from 5.02% to below 5%, comprising direct share holdings and financial instruments including American Depositary Receipts and securities lending arrangements.

WIT - Referenced as a previous employer of Thierry Delaporte, with no specific business implications in this article
BLK - The disclosure is a routine regulatory filing indicating a reduction in shareholding below the mandatory disclosure threshold. This is a factual transaction with no inherent positive or negative implications for BlackRock's operations or strategy.

#BlackRock #Orion Corporation #major shareholder disclosure #stake reduction #5% threshold #Securities Market Act #financial instruments

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

Benzinga • Vandana Singh

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

01/09/2026 08:45 AM • Eli Lilly announced positive Phase 3b trial results for TOGETHER-PsA, showing that combining Taltz (ixekizumab) with Zepbound (tirzepatide) significantly outperforms Taltz alone in treating psoriatic arthritis and obesity. The dual treatment achieved a 31.7% improvement rate versus 0.8% for monotherapy, with a 64% relative increase in ACR50 response rates. Adverse events were mild to moderate and consistent with known safety profiles.

LLY - The company announced successful Phase 3b trial results demonstrating superior efficacy of its dual-drug combination therapy for psoriatic arthritis and obesity. The study met primary and key secondary endpoints with strong clinical outcomes (31.7% vs 0.8% improvement rates) and favorable safety profiles. Stock was up 0.72% in premarket trading and approaching 52-week highs.

#psoriatic arthritis #obesity treatment #Phase 3b trial #Taltz #Zepbound #tirzepatide #ixekizumab #GLP-1 receptor agonist #weight loss

Beyond the Hype: 5 Reasons Quantum Computing Stocks IonQ, Rigetti Computing, and D-Wave Quantum Can Crash in 2026

The Motley Fool • Sean Williams

Beyond the Hype: 5 Reasons Quantum Computing Stocks IonQ, Rigetti Computing, and D-Wave Quantum Can Crash in 2026

01/09/2026 08:36 AM • Despite quantum computing stocks skyrocketing up to 3,290% since October 2024, the article warns of an impending crash in 2026. The author identifies five historical headwinds: early-stage tech bubbles that eventually burst, shareholder dilution from capital raises, extreme valuation multiples (P/S ratios of 100+), an overvalued stock market (CAPE ratio at 41), and low barriers to entry allowing tech giants like Microsoft and Alphabet to compete with first-movers.

SAP - Strengthening European technology ecosystem and developing sovereign AI solutions with a trusted partner
IONQ - Stock has surged 521% since October 2024 but faces extreme valuation (P/S ratio of 100+), ongoing operating losses, shareholder dilution from $2B capital raise, and vulnerability to market corrections given unsustainable early-stage business model.

#quantum computing bubble #stock valuation #early-stage technology #shareholder dilution #market correction #CAPE ratio #price-to-sales ratio

Vistra Wins Mega Nuclear Deal With Meta, Stock Jumps

Benzinga • Lekha Gupta

Vistra Wins Mega Nuclear Deal With Meta, Stock Jumps

01/09/2026 08:32 AM • Vistra Corp secured a 20-year power purchase agreement with Meta Platforms to supply over 2,600 MW of zero-carbon nuclear power from three plants in Ohio and Pennsylvania. The deal, with energy purchases commencing in late 2026, drove Vistra's stock up 15.21% in premarket trading. Meta is simultaneously partnering with Oklo Inc to develop a 1.2-gigawatt nuclear power campus in Ohio, reflecting Big Tech's strategy to secure long-term energy supplies for AI-driven growth.

VST - Secured a major 20-year, 2,600+ MW power purchase agreement with Meta, providing long-term revenue certainty and supporting license extensions for nuclear plants. Stock jumped 15.21% on the announcement.

#nuclear power #power purchase agreement #zero-carbon energy #Meta #Vistra #AI energy demand #license renewal

Rigetti Computing Provides Update on 108-Qubit System

GlobeNewswire Inc. • Na

Rigetti Computing Provides Update on 108-Qubit System

01/09/2026 08:00 AM • Rigetti Computing announced a delay in the general availability of its 108-qubit Cepheus-1-108Q quantum computing system to around the end of Q1 2026. The company cited the need for additional testing and optimization, particularly to address complexities with tunable couplers and achieve its 99.5% median two-qubit gate fidelity target. Despite the delay, Rigetti reported strong progress with current systems achieving 99% fidelity on the 108-qubit system, 99.7% on the 9-qubit system, and 99.6% on the 36-qubit system.

DPZ - Added 348K shares, a 13% increase in position
RGTI - While the company is delaying a major product launch, which is typically negative, the announcement demonstrates commitment to quality and performance standards. The company is making measurable progress on fidelity metrics and has a clear technical roadmap. The delay is framed as a strategic decision to optimize performance rather than a fundamental setback, and the company continues to operate existing systems successfully.

#quantum computing #qubit systems #gate fidelity #product delay #chip optimization #modular architecture #superconducting qubits

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

GlobeNewswire Inc. • Na

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

01/09/2026 08:00 AM • Madrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer to develop ervogastat, a Phase 2 oral DGAT-2 inhibitor for MASH treatment. The deal includes a $50 million upfront payment to Pfizer, with ervogastat positioned as a complementary therapy to Madrigal's approved drug Rezdiffra for potential combination treatment. Madrigal plans to conduct drug-to-drug interaction studies and consult with the FDA on Phase 2 combination trial design in 2026.

CB - Increased position by 16%, buying 4.3 million new shares
MDGL - Madrigal secured an exclusive global license for a promising Phase 2 asset (ervogastat) that complements its approved drug Rezdiffra, strengthening its pipeline and positioning the company for combination therapy development. This strategic expansion demonstrates confidence in the company's MASH treatment leadership and provides multiple value creation opportunities through milestone payments and royalties.

#MASH #ervogastat #DGAT-2 inhibitor #Rezdiffra #combination therapy #liver disease #clinical trial #license agreement

GraniteShares Announces Weekly Distributions for its YieldBOOST FoFs ETFs: YBST and YBTY

GlobeNewswire Inc. • Graniteshares Inc.

GraniteShares Announces Weekly Distributions for its YieldBOOST FoFs ETFs: YBST and YBTY

01/09/2026 08:00 AM • GraniteShares announced weekly distributions for its YieldBOOST Funds of Funds ETFs (YBST and YBTY) with distribution rates of 80.50% and 96.30% respectively. The distributions are based on put option writing strategies that generate income but cap upside potential while exposing investors to downside risk. The company emphasizes that distributions are not guaranteed and may vary significantly.

MERpK - Sold 37 million shares, reducing position by 6%
YBTY - The ETF is presented with factual distribution data ($0.415 per share, 96.30% distribution rate) but accompanied by significant risk warnings regarding put-writing strategy limitations, potential NAV erosion, and lack of upside participation.

#ETF distributions #YieldBOOST #put option strategy #weekly distributions #income generation #YBST #YBTY

The Oncology Institute Announces Leadership Promotions

GlobeNewswire Inc. • Na

The Oncology Institute Announces Leadership Promotions

01/09/2026 08:00 AM • The Oncology Institute promoted Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. Panda brings 25+ years of IT and digital transformation experience from roles at Cisco and Infosys, while Mariano brings 18 years of People Operations experience. The promotions support TOI's growth in value-based cancer care and technology-enabled care delivery.

BMLpL - Sold 37 million shares, reducing position by 6%
TOI - The company is announcing strategic internal promotions of experienced leaders to key executive positions, demonstrating organizational strength, continuity, and commitment to growth. The promotions support the company's expansion in value-based cancer care and technology initiatives, indicating confidence in leadership development and operational advancement.

#Chief Information Officer #Chief People Officer #promotions #oncology #value-based cancer care #digital transformation #AI-enablement #organizational leadership

Gold's 2025 Performance Shifts Ground In ETFs, Central Banks

Benzinga • Stjepan Kalinic

Gold's 2025 Performance Shifts Ground In ETFs, Central Banks

01/09/2026 07:42 AM • Gold achieved stellar 2025 performance with 53 new highs, driving record $89 billion in ETF inflows and $559 billion in global assets under management. Gold surpassed US Treasuries to become the world's largest foreign reserve asset for the first time in nearly three decades, valued at $4 trillion. Central banks are expected to have added another 1,000 tons in 2025, reflecting de-dollarization trends and flight-to-safety demand.

GDX - Benefits from gold's stellar 2025 performance with 53 new highs and strong central bank demand, supporting mining sector valuations.

#gold ETFs #central bank buying #foreign reserves #de-dollarization #record inflows #safe haven assets

Policy Forces Shift Offshore Chinese IPO Tide To Hong Kong From New York

Benzinga • Doug Young

Policy Forces Shift Offshore Chinese IPO Tide To Hong Kong From New York

01/09/2026 07:40 AM • Hong Kong became the world's leading IPO market in 2025, raising $36 billion as Chinese companies shifted listings away from New York. Policy changes by the Hong Kong Stock Exchange, including dual-class share structures and relaxed listing requirements, drove the surge. Meanwhile, Chinese IPO activity in the U.S. plummeted to $1.12 billion, with increasing regulatory hostility and new Nasdaq rules deterring listings.

BBAAY - Mentioned as an example of a company benefiting from Hong Kong's dual-class share structure policy, but no specific business developments or performance metrics discussed.

#Hong Kong IPO market #Chinese companies #policy changes #dual-class shares #U.S. delisting #EV battery makers #tech listings

Wanbang Makes Fourth-Listing Attempt, While Battling Declining Margins

Benzinga • Bamboo Works

Wanbang Makes Fourth-Listing Attempt, While Battling Declining Margins

01/09/2026 07:37 AM • Chinese EV charging equipment provider Wanbang Digital Energy is making its fourth attempt to list on the Hong Kong stock exchange. While the company has become the world's largest supplier of smart charging equipment, it faces significant challenges including declining gross margins (falling from 29.2% to 24.6%), reduced net profits, and volatile cash flows. The company is diversifying into microgrids and energy storage to offset margin pressure in the competitive charging equipment market.

SBGSY - Schneider Electric is mentioned as a strategic partner through a joint venture with Wanbang for European market expansion. While this represents a positive endorsement of Wanbang's business, there is no direct impact on Schneider Electric's operations or financial performance discussed in the article.

#EV charging equipment #IPO listing #declining margins #energy storage #microgrids #Hong Kong stock exchange #cash flow volatility

3 ETFs Set for Explosive Growth in 2026 as Generative AI Adoption Soars

The Motley Fool • Matt Frankel, Cfp

3 ETFs Set for Explosive Growth in 2026 as Generative AI Adoption Soars

01/09/2026 07:31 AM • The article recommends three ETFs for investors seeking generative AI exposure in 2026: the Global X Artificial Intelligence & Technology ETF (AIQ) for direct AI and tech exposure, the Ark Next Generation Internet ETF (ARKW) for actively managed AI-related growth opportunities, and the Vanguard Dividend Appreciation ETF (VIG) for lower-risk AI exposure through dividend-growth stocks.

CGEMY - Mentioned as part of Thierry Delaporte's professional background, with no direct impact on current business performance
AIQ - Recommended as a direct, well-diversified AI exposure option with $7.7B in AUM, 86 holdings, and reasonable 0.68% expense ratio. Not overly concentrated in mega-cap tech.

#generative AI #ETF investment #AI adoption #technology stocks #dividend growth #portfolio diversification

iBio Announces $26 Million Private Placement

GlobeNewswire Inc. • Ibio, Inc.

iBio Announces $26 Million Private Placement

01/09/2026 07:00 AM • iBio, Inc. (NASDAQ: IBIO) announced a private placement financing of approximately $26 million led by Frazier Life Sciences. The company will use proceeds to advance preclinical cardiometabolic programs including IBIO-610 and IBIO-600, extending cash runway into calendar 2028. The offering is expected to close on January 13, 2026.

BMLpJ - Sold 37 million shares, reducing position by 6%
IBIO - The company successfully secured $26 million in funding from quality institutional investors, which extends cash runway into 2028 and enables advancement of multiple preclinical programs. This demonstrates investor confidence and provides financial stability for continued R&D operations.

#private placement #PIPE financing #cardiometabolic programs #antibody therapies #cash runway #preclinical development

Clifton Mining Company (OTCBB: CFTN) (Clifton) -

Benzinga • Prnewswire

Clifton Mining Company (OTCBB: CFTN) (Clifton) - "Board Member Passing"

01/09/2026 07:00 AM • Clifton Mining Company announced the passing of board member K. Bruce Jones, who had previously served on the board in the 1990s and was recently re-elected in October 2025. The company expressed that his knowledge, experience, and professional demeanor will be missed.

BMLpH - Sold 37 million shares, reducing position by 6%
CFTN - The article is a factual announcement of a board member's passing. While the loss of an experienced board member could be viewed negatively, the announcement itself is neutral in tone and does not indicate any operational impact or concerns about the company's future direction.

#board member #passing #death #Clifton Mining #CFTN #OTC Markets

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

GlobeNewswire Inc. • Na

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

01/09/2026 07:00 AM • Aquestive Therapeutics received an FDA letter identifying deficiencies in its Anaphylm (dibutepinephrine) sublingual film NDA that preclude labeling discussions, though the FDA confirmed its review remains ongoing with no final decision made. The company maintains confidence in Anaphylm's potential and is advancing global regulatory expansion in Canada, Europe, and the UK. Aquestive reported approximately $120 million in cash and cash equivalents as of December 31, 2025.

BMLpG - Sold 37 million shares, reducing position by 6%
AQST - The company received an FDA letter identifying unspecified deficiencies in its Anaphylm NDA that preclude labeling discussions, creating regulatory uncertainty and potential delays to the January 31, 2026 PDUSA action date. While management expresses confidence and the company has adequate cash reserves, the identification of deficiencies represents a setback in the approval process for their lead product candidate.

#FDA regulatory deficiencies #Anaphylm sublingual film #NDA approval #epinephrine therapy #global expansion #cash position #clinical development

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

GlobeNewswire Inc. • Na

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

01/09/2026 07:00 AM • MapLight Therapeutics announced that its Phase 2 ZEPHYR trial for ML-007C-MA (schizophrenia treatment) and Phase 2 IRIS trial for ML-004 (autism spectrum disorder) are progressing ahead of schedule, with topline results now expected in Q3 2026. The company cited accelerated enrollment pace and disciplined execution as drivers of the timeline acceleration.

BACpS - Sold 37 million shares, reducing position by 6%
MPLT - The company reported accelerated enrollment in its Phase 2 trials ahead of schedule, demonstrating strong execution and momentum in clinical development. The narrowed timing guidance to Q3 2026 for both ZEPHYR and IRIS trials indicates progress and operational efficiency, which are positive indicators for investors and stakeholders.

#Phase 2 clinical trials #ZEPHYR trial #IRIS trial #schizophrenia #autism spectrum disorder #topline results #enrollment acceleration #CNS disorders

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

GlobeNewswire Inc. • Amarin Corporation Plc

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

01/09/2026 07:00 AM • Amarin Corporation announced that its VASCEPA/VAZKEPA (icosapent ethyl) franchise is well-positioned to benefit from recent breakthroughs in elevated triglyceride therapies. The company highlighted that new ApoC-III-targeted injectables complement rather than compete with VASCEPA, which has been prescribed over 25 million times globally. Amarin expects payor-driven step-therapy programs to increase utilization of VASCEPA as a cost-effective first-line therapy before access to newer, more expensive alternatives. The company also secured an exclusive long-term license agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries in Europe.

BACpQ - Sold 37 million shares, reducing position by 6%
RICFY - Recordati secured an exclusive long-term license and supply agreement to commercialize VAZKEPA across 59 countries in Europe, representing a significant commercial opportunity with patent protection extending until 2039.

#VASCEPA #VAZKEPA #icosapent ethyl #elevated triglycerides #cardiovascular disease #step-therapy programs #ApoC-III injectables #REDUCE-IT trial #Recordati agreement